Tivorbex (nanotechnology formulated indomethacin) / Iroko - LARVOL DELTA

Small-Scale Aqueous Suspension Preparation using Dual Centrifugation: The Effect of Process Parameters on the Sizes of Drug Particles. (PubMed, Eur J Pharm Sci) - "In the present work, the rate of size reduction on three different model compounds, i.e., cinnarizine, haloperidol, and indomethacin, was found to be mostly influenced by the milling speed, size of milling beads, and the bead loading during milling, whereas the rotor temperature did not affect the particle size profiles when stabilized with polysorbate 20 during milling with dual centrifugation...These observations were further supported by the color conversion from white to yellow of indomethacin suspensions which indicated generation of small quantities of amorphic material after milling with a high milling intensity. Upscale investigations showed comparable particle size profiles for all three model compounds while milling at 1500 rpm for five minutes."

Journal

Multifunctional Indomethacin Conjugates for the Development of Nanosystems Targeting Cancer Treatment. (PubMed, Int J Nanomedicine) - "While free IND was active at a concentration of 270.5 μM, in the form of the phospholipid conjugate (IND-OA-PC), it inhibited the growth of cancer cells at 67.5 μM and after conjugate encapsulation (IND-OA-PC-NLC) it was effective at only 10.3 μM. Our study revealed that the conjugation of NSAID with phosphatidylcholine and its combination with nanotechnology techniques create opportunities to repurpose well-known drugs from this group for new therapeutic applications."

Journal • Breast Cancer • Gastrointestinal Disorder • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • HER-2

The Protecting Role of Black Seed Oil and Its Nano-Formulation in LPS-Induced Acute Kidney Injury in Mice: Evaluation of Oxidative Stress, Biochemical & Molecular Parameters. (PubMed, J Inflamm Res) - "It also aimed to compare their anti-inflammatory activity with indomethacin, a known synthetic anti-inflammatory drug...Their protective effect against pathological alterations in kidney tissues was significantly noticed. BSO and its nano-formulation could be used as nephroprotective and anti-inflammatory supplements."

IO biomarker • Journal • Preclinical • Acute Kidney Injury • Infectious Disease • Inflammation • Nephrology • Oncology • Renal Disease • KIM1 • LCN2 • TLR4 • TNFA

A novel nano-formulation of olmesartan medoxomil with improved delivery and efficacy in the treatment of indomethacin-induced duodenitis in rats. (PubMed, Braz J Med Biol Res) - "OMZ was more effective in protecting the duodenum from indomethacin-induced injuries compared to OM due to improved delivery, higher bioavailability, and better anti-inflammatory, antioxidant, and antiapoptotic effects. OMZ could be a better choice for hypertensive patients with non-steroidal anti-inflammatory drugs-induced duodenitis."

IO biomarker • Journal • Preclinical • Lymphoma • Oncology • BAX • BIRC5 • CASP3 • IL6 • MPO • NFKB1 • NF-κβ • RELA • TNFA

Novel Injectable Fluorescent Polymeric Nanocarriers for Intervertebral Disc Application. (PubMed, J Funct Biomater) - "Two drugs, a water insoluble indomethacin (IND) and a water soluble 4-aminopyridine (4-AP), were used to study their release patterns...When injected into coccygeal mouse IVDs in vivo, the nanoparticles remained within the nucleus pulposus cells and the injection site of the nucleus pulposus and annulus fibrosus of the IVD. These fluorescent nano-formulations may serve as a platform technology to deliver therapeutic agents to IVDs and other tissues that require localized drug injections."

Journal • Fibrosis • Pain

Incidence, Risk Factors, and Outcomes of Neonatal AKI in Very Low Birth Weight Infants: A Retrospective Cohort Study in a Single Neonatal Intensive Care Unit in Japan (KIDNEY WEEK 2022) - "Conclusion Early diagnosis and timely intervention in neonates who treated with indomethacin can prevent the progression of AKI and thus improve prognoses. We suggest that those neonates should be followed up for a long term to prevent CKD. Demographic of VLBW infants with AKI and no-AKI"

Retrospective data • Chronic Kidney Disease • Critical care • Gynecology • Nephrology • Renal Disease • Small for Gestational Age

Topical nanocarriers for management of Rheumatoid Arthritis: A review. (PubMed, Biomed Pharmacother) - "The treatment regimen for RA involves frequent drug administration and high doses of NSAIDs such as indomethacin, diclofenac, ibuprofen, celecoxib, etorcoxib...These drug delivery systems are non-toxic and have high drug encapsulation efficiency and they also provide sustained release of drug. This review discusses the effect of formulation composition on the physiochemical properties of these nanocarriers in terms of particle size, surface charge, drug entrapment and also drug release profile thus providing a landscape of topically used nanoformulations for symptomatic treatment of RA."

Journal • Review • Gastrointestinal Disorder • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

iCeutica receives key patent for SoluMatrix Fine Particle Technology platform (Businesswire) - "ICeutica Inc., today announced that its wholly owned subsidiary has been awarded a key patent for its SoluMatrix Fine Particle Technology™ platform by the U.S. Patent and Trademark Office (USPTO). The patent...covers the company’s dry milling method for producing submicron-sized particles that are 10 to 200 times smaller than conventional drug particles."

Patent • Pain

In brief: low-dose indomethacin (Tivorbex) for pain (Med Lett Drugs Ther) - Abstract not available.

Review • Pain

Iroko to present phase 3 data from submicron NSAID portfolio at American College of Rheumatology Annual Scientific Meeting (Businesswire) - "Iroko Pharmaceuticals...announced today that data from Phase 3 studies of Iroko’s investigational non-steroidal anti-inflammatory drugs (NSAIDs) submicron diclofenac and submicron indomethacin will be presented in poster sessions at the upcoming 2013 American College of Rheumatology (ACR) Annual Scientific Meeting, taking place in San Diego, from October 25-30."

Anticipated P3 data • Pain

Zyla Life Sciences reports third quarter 2019 financial results (PRNewswire) - "Zyla Life Sciences...today reported financial results for the third quarter ended September 30, 2019, including net sales from commercial products: SPRIX® (ketorolac tromethamine) Nasal Spray, the SoluMatrix® products, VIVLODEX® (meloxicam), TIVORBEX® (indomethacin) and ZORVOLEX® (diclofenac)), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII....Net product sales were $22.4 million for the three months ended September 30, 2019 compared to $8.2 million for the three months ended September 30, 2018. The increase was largely due to the addition of the five acquired products at the end of January 2019."

Sales

Zyla Life Sciences to present at and participate in a panel at the 2019 Disruptive Growth Conference on September 5, 2019 (PRNewswire) - "Zyla Life Sciences...announced that Bob Radie, president and chief executive officer of Zyla, will give a corporate presentation and participate in a panel at the 2019 Disruptive Growth Conference....The presentation will include a review of Zyla's commercial products: SPRIX® (ketorolac tromethamine) Nasal Spray, the SoluMatrix® products, VIVLODEX® (meloxicam), TIVORBEX® (indomethacin) and ZORVOLEX® (diclofenac), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only –CII."

Clinical